EPO and cerebral palsy: There were no differences between groups with respect to the percentage of infants with Bayley-II Mental Developmental Index <70 (34% EPO and 36% placebo/control), moderate to severe cerebral palsy (16% EPO and 18% placebo/control) or the percentage of infants with any of the above-described neurodevelopmental impairments (42% EPO and 44% placebo/control) (41).